Phio Pharmaceuticals appoints Robert Infarinato as CFO effective August 1, 2024

Phio Pharmaceuticals Corp.

Robert M. Infarinato appointed VP & CFO effective August 1, 2024; will serve as principal financial and accounting officer.
Mr. Infarinato, 78, is an attorney and CPA with over 20 years of financial leadership in pharma and biotech.
Base salary $180,000; eligible for annual bonus up to 30% of base based on performance goals.
Caitlin Kontulis ceased as principal accounting officer on August 1 and will leave employment on August 31, 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Caitlin Kontulis

Vice President of Finance and Administration and Secretary

PHIO · Phio Pharmaceuticals Corp.

Effective: 2024-08-01
Successor: Robert M. Infarinato
Filed: August 1, 2024, 7:59 PM ET

Caitlin Kontulis, Vice President of Finance and Administration and Secretary of the Company, ceased serving as the Company’s principal accounting officer, effective as of August 1, 2024, with her employment terminating on August 31, 2024.

Appointed

Robert M. Infarinato

Vice President, Chief Financial Officer

PHIO · Phio Pharmaceuticals Corp.

Effective: 2024-08-01
Filed: August 1, 2024, 7:59 PM ET

On July 15, 2024, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert M. Infarinato to serve as the Company’s Vice President, Chief Financial Officer and designated him as the Company’s principal financial officer and principal accounting officer, effective as of August 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Caitlin Kontulis departed as Vice President of Finance and Administration and Secretary at Phio Pharmaceuticals Corp..

Action: ceased serving
Role: Vice President of Finance and Administration and Secretary

Exact text from the filing

Caitlin Kontulis, Vice President of Finance and Administration and Secretary of the Company, ceased serving as the Company’s principal accounting officer, effective as of August 1, 2024, with her employment terminating on August 31, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert M. Infarinato was appointed as Vice President, Chief Financial Officer at Phio Pharmaceuticals Corp..

Action: appointed
Role: Vice President, Chief Financial Officer

Exact text from the filing

On July 15, 2024, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert M. Infarinato to serve as the Company’s Vice President, Chief Financial Officer and designated him as the Company’s principal financial officer and principal accounting officer, effective as of August 1, 2024.

View on SEC.gov

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-24-005194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.